ASCO vs. BIO: A Scheduling And Exhibit Hall Culture Clash
The two massive conferences overlapped in early June, causing scheduling angst for some firms – and highlighting the difference between events focused on data and those focused on deal-making.
You may also be interested in...
Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.
Pink Sheet reporters and editor discuss the latest coronavirus vaccine news, CMS’ effect on the future of aducanumab, as well as new assessment goals for PDUFA VII.